Last reviewed · How we verify
calcium sensing receptor agonist
Chulalongkorn University's calcium sensing receptor agonist is a marketed drug with a key composition patent expiring in 2028. The drug's market position is bolstered by its unique mechanism of action, which differentiates it from existing treatments. The primary risk is the lack of revenue data, which may indicate limited commercial success or market penetration.
At a glance
| Generic name | calcium sensing receptor agonist |
|---|---|
| Also known as | Regpara |
| Sponsor | Chulalongkorn University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Bone Markers and Bone Density Changes in Hyperperparathyroid Dialysis Patients Under Cinacalcet Treatment (NA)
- The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- calcium sensing receptor agonist CI brief — competitive landscape report
- calcium sensing receptor agonist updates RSS · CI watch RSS
- Chulalongkorn University portfolio CI